-
1
Vitiligo is a chronic autoimmune disease characterized by hypopigmented or depigmented skin patches, affecting quality of life.
-
2
Conventional treatments for vitiligo, including corticosteroids and phototherapy, often have limited long-term efficacy.
-
3
Recent research highlights the potential of Janus kinase (JAK) inhibitors as a novel therapeutic option for vitiligo.
-
4
Clinical trials have shown specific JAK inhibitors, such as ruxolitinib, upadacitinib, and abrocitinib, to promote skin repigmentation.
-
5
The review synthesizes current evidence on the mechanisms, efficacy, and safety profiles of JAK inhibitors in vitiligo management.
